



Lasa Supergenerics Limited

Q3FY21 Earnings Conference Call

Friday, 05th February 2021 at 01:00 p.m.

Wednesday, 03th February 2021: Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the third quarter ended December 31st 2020 (Q3FY21).

It will organize an earnings conference call on Friday, 05th February 2021 @ 01:00 p.m. to discuss the Company's Q3FY21 financial performance.

Dr. Omkar Herlekar - Chairperson & Managing Director will represent LASA Supergenerics Limited on the call.

The financial results are available on the corporate website - <https://lasalabs.com>.

DETAILS OF THE CONFERENCE CALL

Timing	01:00p.m. IST on Friday, 05th February 2021
Diamond Pass	Click Here
Conference dial-in Primary number	91 22 6280 1554 / 91 22 7115 8374
Local Access Number	91-7045671221
Hong Kong Local Access Number	800964448 / 852 30186877
Singapore Local Access Number	8001012045 / 65 31575746
UK Local Access Number	08081011573 / 44 2034785524
USA Local Access Number	18667462133/ 1 3233868721

About Lasa Supergenerics Limited (www.lasalabs.com/; BSE: 540702; NSE: LASA)

Incorporated in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to countries like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more information contact:

Mr. Hitesh Wadhvani

Lasa Supergenerics Ltd.

Tel: 7798888147

E-mail: hitesh@lasalabs.com
